Rep. Lisa C. McClain Purchases Shares of AbbVie Inc. (NYSE:ABBV)

Posted by Casey Walker on Nov 27th, 2025

Representative Lisa C. McClain (R-Michigan) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in AbbVie stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

AbbVie Price Performance

ABBV stock opened at $227.57 on Thursday. The business’s fifty day moving average price is $227.51 and its 200 day moving average price is $206.27. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The company has a market capitalization of $402.20 billion, a PE ratio of 108.37, a P/E/G ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s payout ratio is presently 524.24%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Piper Sandler restated an “overweight” rating and issued a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Erste Group Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Wells Fargo & Company increased their price objective on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Hsbc Global Res cut AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Finally, DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research note on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $241.85.

Read Our Latest Research Report on AbbVie

Institutional Trading of AbbVie

A number of hedge funds and other institutional investors have recently bought and sold shares of ABBV. Vermillion & White Wealth Management Group LLC boosted its position in shares of AbbVie by 140.0% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 432 shares of the company’s stock worth $100,000 after acquiring an additional 252 shares in the last quarter. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of AbbVie during the 3rd quarter worth about $212,000. Alexander Labrunerie & CO. Inc. lifted its stake in AbbVie by 15.6% during the third quarter. Alexander Labrunerie & CO. Inc. now owns 1,322 shares of the company’s stock worth $306,000 after purchasing an additional 178 shares during the last quarter. Chelsea Counsel Co. purchased a new position in AbbVie in the third quarter valued at approximately $26,000. Finally, CIBC Private Wealth Group LLC increased its stake in AbbVie by 1.1% in the third quarter. CIBC Private Wealth Group LLC now owns 1,179,751 shares of the company’s stock valued at $273,159,000 after purchasing an additional 13,087 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

AbbVie Company Profile

(Get Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.